Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 2 · newest first

  1. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategiesCancer Drug Resistance · 2025
  2. Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistanceCancer Drug Resistance · 2025
  3. Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cellsCancer Drug Resistance · 2025
  4. New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancerCancer Drug Resistance · 2025
  5. ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancerCancer Drug Resistance · 2025
  6. Resistance signatures manifested in early drug response across cancer types and speciesCancer Drug Resistance · 2025
  7. IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancerCancer Drug Resistance · 2025
  8. Effects of FAP⁺ cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4⁺ T cell polarization in gastric cancerCancer Drug Resistance · 2025
  9. Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expressionCancer Drug Resistance · 2025
  10. Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesCancer Drug Resistance · 2025
  11. CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axisCancer Drug Resistance · 2025
  12. The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapyCancer Drug Resistance · 2025
  13. Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCCCancer Drug Resistance · 2025
  14. Modeling methods of different tumor organoids and their application in tumor drug resistance researchCancer Drug Resistance · 2025
  15. Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancerCancer Drug Resistance · 2025
  16. MicroRNA-mediated autophagy regulation in thyroid cancer drug resistanceCancer Drug Resistance · 2025
  17. Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategiesCancer Drug Resistance · 2025
  18. Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumorsCancer Drug Resistance · 2025
  19. Acquired resistance to molecularly targeted therapies for cancerCancer Drug Resistance · 2025
  20. PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinomaCancer Drug Resistance · 2025
  21. ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLCCancer Drug Resistance · 2025
  22. Advances in the application of patient-derived xenograft models in acute leukemia resistanceCancer Drug Resistance · 2025
  23. Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancerCancer Drug Resistance · 2025
  24. Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformationCancer Drug Resistance · 2025
  25. Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemnessCancer Drug Resistance · 2025
  26. The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistanceCancer Drug Resistance · 2025
  27. Mechanisms of resistance to NAMPT inhibitors in cancerCancer Drug Resistance · 2025
  28. Circular RNAs modulate cancer drug resistance: advances and challengesCancer Drug Resistance · 2025
  29. Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AMLCancer Drug Resistance · 2025
  30. Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosisCancer Drug Resistance · 2025
  31. Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathwaysCancer Drug Resistance · 2025
  32. Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer typesCancer Drug Resistance · 2025
  33. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencingCancer Drug Resistance · 2025
  34. Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinomaCancer Drug Resistance · 2025
  35. The epigenetic mechanisms involved in the treatment resistance of glioblastomaCancer Drug Resistance · 2025
  36. Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesCancer Drug Resistance · 2025
  37. Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapyCancer Drug Resistance · 2025
  38. Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistanceCancer Drug Resistance · 2025
  39. Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancersCancer Drug Resistance · 2025
  40. Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progressionCancer Drug Resistance · 2025
  41. Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancersCancer Drug Resistance · 2025
  42. Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinomaCancer Drug Resistance · 2025
  43. Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironmentCancer Drug Resistance · 2025
  44. Ferroptosis-related signaling pathways in cancer drug resistanceCancer Drug Resistance · 2025
  45. Mechanisms of immunotherapy resistance in small cell lung cancerCancer Drug Resistance · 2024
  46. Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumorsCancer Drug Resistance · 2024
  47. Ovarian tumor microenvironment contributes to tumor progression and chemoresistanceCancer Drug Resistance · 2024
  48. Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancerCancer Drug Resistance · 2024
  49. Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatmentCancer Drug Resistance · 2024
  50. The emerging role of GLP-1 receptor agonists in treating or preventing cancerCancer Drug Resistance · 2024